Pain and HAQ-DI for studies included in the MAIC
| RA-BEGIN9 | AMBITION10 | FUNCTION8 | PREMIER6 7 | ORAL-START11 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Endpoint values at baseline and either change from baseline or mean values at 6 months | MTX (N=210) | Baricitinib 4 mg (N=159) | MTX (N=284) | Tocilizumab 8 mg/kg (N=286) | MTX (N=287) | Tocilizumab 8 mg/kg (N=292) | MTX (N=257) | Adalimumab 40 mg (N=274) | MTX (N=186) | Tofacitinib 5 mg (N=373) |
|
Patient’s assessment of pain, 0–100 mm VAS | ||||||||||
| Baseline | 65 | 64 | 62 | 59 | 60 | 63 | 60 | 65 | 59 | 59 |
| 6 months | −30 | −41 | −31 | −35 | −34 | −36 | Adjusted absolute mean:* 29 |
Adjusted absolute mean*: 31 | −28 | −32 |
| HAQ-DI, 0-3 | ||||||||||
| Baseline | 1.7 | 1.6 | 1.5 | 1.6 | 1.5 | 1.6 | 1.5 | 1.6 | 1.5 | 1.5 |
| 6 months | −0.7 | −1.0 | −0.5 | −0.7 |
−0.04 (vs MTX) | Adjusted absolute mean*: 0.9 |
Adjusted absolute mean*: 0.9 | −0.6 | −0.8 | |
*Adjusted mean scores, rather than change from baseline, were reported in Strand et al.7
HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate; VAS, visual analogue scale. Pain and HAQ-DI were collected at 6 months or 24±2 weeks.